GRAND RAPIDS, Mich. (WOOD) — A local drug developer is one step closer to releasing a potential treatment for a form of autism that could also help those with Alzheimer's disease.
Grand Rapids-based Tetra Discovery Partners Incorporated is the developer. The company has received clearance from the federal Food and Drug Administration to move on to phase two of testing, which means a clinical trial on humans will start soon.
"We're hoping that this drug will have significant impact on the quality of patients' lives," Tetra Chairman and CEO Mark Gurney said.
The drug is focused to treat Fragile X syndrome, the most common genetic form of autism.
Two of Kathy Proulx's sons were born with Fragile X syndrome.
"There are some facial features, if you are aware of them — kind of elongated face, kind of larger ears, but my husband's family has larger ears so we didn't notice it," she said.
Full story: WOOD TV